Last reviewed · How we verify
NCT06933537
Effectiveness of Personalized Alternating Current Stimulation for Treating Emotional Disorders in CNS Demyelination Patients
NA trial testing Neuroelectrics StarStim 32 in Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System in 65 participants. Currently enrolling.
1 July 2027
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 65 |
| Start date | 29 December 2024 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neuroelectrics StarStim 32
- Neuroelectrics StarStim 32
Conditions studied
- Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System — all drugs for Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System →
Sponsor
Xuanwu Hospital, Beijing
Who can join
Adults 18 to 65, any sex, with Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the efficacy of personalized alternating current stimulation in the treatment of emotional disorders in patients with inflammatory demyelination of the central nervous system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06933537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neuroelectrics StarStim 32
Trials testing the same drug.
- NCT06968039 — Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Pat · NA · recruiting
Other recruiting trials for Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Currently open trials in the same condition.
- NCT07087873 — Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiop · NA · recruiting
- NCT06942611 — Transcranial Electrical Stimulation for Treating Chronic Pain in Inflammatory Demyelinating Diseases · NA · recruiting
- NCT07029386 — Effects of Transcranial Electrical Stimulation on Cognitive Impairment in CNS Inflammatory Demyelinating Diseases · NA · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06933537 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 18 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06933537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing